These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2888737)

  • 21. Lipid profile improvement following celiprolol.
    Herrmann JM; von Heyman F; Freischütz G
    J Int Med Res; 1988; 16 Suppl 1():39A-46A. PubMed ID: 2906016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes in lipids and lipoproteins caused by the beta-blocking agents used as antihypertensives].
    Rouffy J; Chanu B; Bakir R; Sauvanet JP
    J Pharmacol; 1983; 14 Suppl 2():183-99. PubMed ID: 6138467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension.
    Farsang C; Péter M; Balás-Eltes A; Fehér J
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S240-3. PubMed ID: 2455187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension.
    Fogari R; Zoppi A; Pasotti C; Poletti L; Tettamanti F; Maiwald C
    Int J Clin Pharmacol Ther Toxicol; 1988 Dec; 26(12):597-604. PubMed ID: 2905341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension.
    Lacourcière Y; Gagné C
    J Hum Hypertens; 1993 Apr; 7(2):149-52. PubMed ID: 8510087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emerging problem of plasma lipid changes during antihypertensive therapy.
    Johnson BF
    J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S213-21. PubMed ID: 6177959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P; de Courten M; Ferrari P; Böhlen L
    J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum lipids. lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or phenytoin].
    Pita-Calandre E; Rodríguez-López CM; Cano MD; Peña-Bernal M
    Rev Neurol; 1998 Nov; 27(159):785-9. PubMed ID: 9859151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oxprenolol treatment on pseudocholinesterase and lipids in rats.
    Krnić Z; Bradamante V
    Arzneimittelforschung; 1997 Aug; 47(8):910-3. PubMed ID: 9296276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of beta 2-adrenergic stimulation on serum lipids.
    Lehtonen A; Viikari J; Sallinen VP; Elo J
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):530-1. PubMed ID: 6129199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison.
    Spence JD; Huff M; Barnett PA
    Can J Clin Pharmacol; 2000; 7(1):32-7. PubMed ID: 10822211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
    Zanchetti A
    Blood Press Suppl; 1995; 3():38-46. PubMed ID: 8535541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension.
    Frithz G; Weiner L
    Eur J Clin Pharmacol; 1987; 32(1):77-80. PubMed ID: 2884116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of tertatolol on atherogenicity indices in normo- or dis-lipemic hypertensive patients].
    Richard JL; Jacotot B
    Ann Med Interne (Paris); 1987; 138 Suppl 1():35-8. PubMed ID: 2884915
    [No Abstract]   [Full Text] [Related]  

  • 36. [Adrenergic mechanisms and their significance for plasma lipid concentrations].
    Day JL
    Wien Med Wochenschr; 1982; 132 Spec No 2():19-22. PubMed ID: 6132497
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats.
    Bradamante V; Krnić Z; Zrinski R; Konjevoda P; Reiner Z
    Arzneimittelforschung; 2006; 56(2):64-9. PubMed ID: 16572919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol.
    Välimäki M; Maass L; Harno K; Nikkilä EA
    Eur J Clin Pharmacol; 1986; 30(1):17-20. PubMed ID: 3709628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of atenolol on plasma HDL cholesterol subfractions.
    Lehtonen A; Marniemi J
    Atherosclerosis; 1984; 51(2-3):335-8. PubMed ID: 6743386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension.
    van Brummelen P; Gevers Leuven JA; van Gent CM
    Curr Med Res Opin; 1979; 6(1):24-9. PubMed ID: 222539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.